| Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene |
ACTRN12620001286932: Investigating the effect of a virus-based immunotherapy as a pre-surgical treatment for prostate cancer |
|
|
| Recruiting | 2 | 30 | | | Royal Melbourne Hospital, Movember, Medical Research Future Fund | Prostate Cancer | | | | |
| Active, not recruiting | 1b/2a | 89 | US, RoW | Pexastimogene Devacirepvec (Pexa-Vec), JX-594, Cemiplimab | SillaJen, Inc., Regeneron Pharmaceuticals | Renal Cell Carcinoma | 08/23 | 11/23 | | |
2016-000085-32: The purpose of this study is to evaluate the safety and efficacy of the combination of two products Pexa-Vec and nivolumab for the treatment of liver cancer L'obiettivo dello studio clinico è di valutare la sicurezza e l'efficacia della combinazione dei due prodotti Pexa-Vec e nivolumab per il trattamento del tumore del fegato |
|
|
| Not yet recruiting | 1/2 | 55 | Europe | pexastimogene devacirepvec, nivolumab, [Pexa-Vec], [nivolumab], Suspension for injection, Concentrate for solution for infusion, OPDIVO - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 4 ML- 1 FLACONCINO | TRANSGENE SA, TRANSGENE | Hepatocellular carcinoma Carcinoma epatocellulare, Liver cancer Tumore del fegato, Diseases [C] - Cancer [C04] | | | | |
NCT03206073: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer |
|
|
| Completed | 1/2 | 34 | US | Durvalumab, MEDI-4736, Tremelimumab, CP-675,206, Pexa-Vec, Pexa-Vec, INN pexastimogene devacirepvec | National Cancer Institute (NCI) | Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms | 09/20 | 06/22 | | |
|
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma |
|
|
| Recruiting | 1/2 | 54 | RoW | Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy | Lee's Pharmaceutical Limited | Local Progression or Metastatic Melanoma With Failed First-line Treatment | 05/22 | 05/23 | | |
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma |
|
|
| Recruiting | 1/2 | 197 | Europe | Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab | Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene | Solid Tumors, Soft-tissue Sarcoma, Breast Cancer | 05/23 | 11/24 | | |
|
